Sun Pharma Arm SPARC to Monetise PRV for USD 195 Million
New Delhi: Sun Pharma Advanced Research Company Ltd on Thursday said it will sell its rare paediatric disease priority review voucher for USD195 million to an undisclosed buyer.
The company has entered into a definitive asset purchase agreement to sell its rare paediatric disease priority review voucher (PRV) for $195 million upon the closing of the transaction,Sun Pharma Advanced Research Company Ltd (SPARC) said in a regulatory filing.
PRV was granted by the US Food and Drug Administration (USFDA) for the approval of Sezaby indicated for the treatment of neonatal seizures, it added.
As per the USFDA companies which create drugs for neglected diseases are given a voucher for use on another drug which will expedite the review process.
"The sale of the PRV will enable us to accelerate the development of our pipeline assets and strengthen our external innovation strategy, which has already delivered multiple additions to our portfolio," SPARC CEO Anil Raghavan said.
The transaction is subject to customary closing conditions, the company said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.